CN115677597B - New preparation method of ticagrelor intermediate - Google Patents
New preparation method of ticagrelor intermediate Download PDFInfo
- Publication number
- CN115677597B CN115677597B CN202211395626.8A CN202211395626A CN115677597B CN 115677597 B CN115677597 B CN 115677597B CN 202211395626 A CN202211395626 A CN 202211395626A CN 115677597 B CN115677597 B CN 115677597B
- Authority
- CN
- China
- Prior art keywords
- compound
- preparation
- ticagrelor
- novel
- intermediate according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- PYEJQVYISBUGDU-UHFFFAOYSA-N 2-(3,4-difluorophenyl)cyclopropane-1-carboxamide Chemical compound NC(=O)C1CC1C1=CC=C(F)C(F)=C1 PYEJQVYISBUGDU-UHFFFAOYSA-N 0.000 title claims abstract description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 30
- 150000001875 compounds Chemical class 0.000 claims description 28
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 claims description 22
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 claims description 16
- 239000003054 catalyst Substances 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 14
- 230000008569 process Effects 0.000 claims description 13
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 claims description 12
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 11
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 claims description 10
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 10
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 claims description 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 8
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 claims description 8
- 239000002585 base Substances 0.000 claims description 8
- 239000012320 chlorinating reagent Substances 0.000 claims description 8
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical class CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 claims description 7
- YSNXOQGDHGUKCZ-UHFFFAOYSA-N n-benzylhydroxylamine;hydron;chloride Chemical class Cl.ONCC1=CC=CC=C1 YSNXOQGDHGUKCZ-UHFFFAOYSA-N 0.000 claims description 7
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 claims description 6
- 238000005984 hydrogenation reaction Methods 0.000 claims description 5
- 229910052751 metal Inorganic materials 0.000 claims description 5
- 239000002184 metal Substances 0.000 claims description 5
- 230000009467 reduction Effects 0.000 claims description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- 239000003513 alkali Substances 0.000 claims description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 claims description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 4
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 claims description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 claims description 4
- 229910017604 nitric acid Inorganic materials 0.000 claims description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 2
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 claims description 2
- 230000009471 action Effects 0.000 claims description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- BSIDXUHWUKTRQL-UHFFFAOYSA-N nickel palladium Chemical compound [Ni].[Pd] BSIDXUHWUKTRQL-UHFFFAOYSA-N 0.000 claims description 2
- 229910052697 platinum Inorganic materials 0.000 claims description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 claims description 2
- 239000000377 silicon dioxide Substances 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 abstract description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 16
- 230000000052 comparative effect Effects 0.000 description 15
- 230000015572 biosynthetic process Effects 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- YVWGMAFXEJHFRO-UHFFFAOYSA-N halopropane Chemical compound FC(F)C(F)(F)CBr YVWGMAFXEJHFRO-UHFFFAOYSA-N 0.000 description 6
- 229950000188 halopropane Drugs 0.000 description 6
- OJURWUUOVGOHJZ-UHFFFAOYSA-N methyl 2-[(2-acetyloxyphenyl)methyl-[2-[(2-acetyloxyphenyl)methyl-(2-methoxy-2-oxoethyl)amino]ethyl]amino]acetate Chemical compound C=1C=CC=C(OC(C)=O)C=1CN(CC(=O)OC)CCN(CC(=O)OC)CC1=CC=CC=C1OC(C)=O OJURWUUOVGOHJZ-UHFFFAOYSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 5
- STUQITWXBMZUGY-UHFFFAOYSA-N 6-hydroxy-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound OC1=CC(O)=NC(S)=N1 STUQITWXBMZUGY-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- IYXGSMUGOJNHAZ-UHFFFAOYSA-N Ethyl malonate Chemical compound CCOC(=O)CC(=O)OCC IYXGSMUGOJNHAZ-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- SNMVRZFUUCLYTO-UHFFFAOYSA-N n-propyl chloride Chemical compound CCCCl SNMVRZFUUCLYTO-UHFFFAOYSA-N 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- CYNYIHKIEHGYOZ-UHFFFAOYSA-N 1-bromopropane Chemical compound CCCBr CYNYIHKIEHGYOZ-UHFFFAOYSA-N 0.000 description 2
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- BEPAFCGSDWSTEL-UHFFFAOYSA-N dimethyl malonate Chemical compound COC(=O)CC(=O)OC BEPAFCGSDWSTEL-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- ULYZAYCEDJDHCC-UHFFFAOYSA-N isopropyl chloride Chemical compound CC(C)Cl ULYZAYCEDJDHCC-UHFFFAOYSA-N 0.000 description 2
- 210000001503 joint Anatomy 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- OEKWJQXRCDYSHL-FNOIDJSQSA-N ticagrelor Chemical compound C1([C@@H]2C[C@H]2NC=2N=C(N=C3N([C@H]4[C@@H]([C@H](O)[C@@H](OCCO)C4)O)N=NC3=2)SCCC)=CC=C(F)C(F)=C1 OEKWJQXRCDYSHL-FNOIDJSQSA-N 0.000 description 2
- 229960002528 ticagrelor Drugs 0.000 description 2
- NAMYKGVDVNBCFQ-UHFFFAOYSA-N 2-bromopropane Chemical compound CC(C)Br NAMYKGVDVNBCFQ-UHFFFAOYSA-N 0.000 description 1
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 150000002367 halogens Chemical group 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- FMKOJHQHASLBPH-UHFFFAOYSA-N isopropyl iodide Chemical compound CC(C)I FMKOJHQHASLBPH-UHFFFAOYSA-N 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- 238000011112 process operation Methods 0.000 description 1
- 108091006082 receptor inhibitors Proteins 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 238000006257 total synthesis reaction Methods 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
The invention relates to the technical field of organic synthesis, in particular to a novel preparation method of ticagrelor intermediate. Compared with the scheme disclosed in the prior art, the preparation process is simpler, the yield is higher, and the cost is lower.
Description
Technical Field
The invention belongs to the field of organic synthesis, in particular to the field of organic medicine synthesis, and more particularly relates to a novel preparation method of ticagrelor intermediates.
Background
Ticagrelor is an oral selective P2Y12 receptor inhibitor developed by aslicon, uk, and can prevent platelet activation and aggregation caused by ADP, reduce the probability of cardiovascular death, acute Coronary Syndrome (ACS) in patients with myocardial infarction and stroke, and the historical rate of Myocardial Infarction (MI).
Compound v is an important intermediate for the preparation of ticagrelor, the structure of which is shown below:
one route to compound V is given in US 5654285:
the process routes for preparing compound V from thiobarbituric acid are reported in WO2005095358, US2011071290, WO2012138981 and the like,
another method for the preparation of compound V is disclosed in CN103772295 a:
a preparation method is reported in the literature Springer plus,2015,4 (1): 1-11, and comprises the following main steps:
in the process, the bromopropane is firstly cyclized and then butted, and under the synthesis mode, the butting difficulty is high and the yield is low.
Disclosure of Invention
The invention aims to solve the technical problems that the synthesis thought disclosed by America of Ticager Lei Yuan research company is limited, and a synthesis process of looping and then butt joint of bromopropane is adopted, so that the process has high butt joint difficulty and low yield, and the total synthesis yield of an intermediate compound V is low and the process difficulty is high.
In order to solve the problems, the invention discloses a novel preparation method of ticagrelor intermediates, and the synthetic route comprises the following steps:
(1) Thiourea and halogenated propane react and are butted to synthesize the compound I,
x is halogen;
(2) The compound I and malonate synthesize a compound II under the action of alkali,
r1 and R2 are C1-C6 alkyl;
(3) The compound II is nitrified, chloridized and reduced to obtain a compound V,
further, in the step (1), the molar ratio of halogenated propane to thiourea is 1:1-2, preferably 1:1.2.
further, in the step (2), the molar ratio of the compound I, the malonate and the base is 1: 1-2: 1 to 2, preferably 1:1.2:1.2.
further, in the step (2), the alkali may be one or more of potassium carbonate, sodium carbonate, potassium hydroxide, sodium hydroxide, potassium tert-butoxide, sodium tert-butoxide and sodium methoxide, and preferably sodium methoxide.
Further, in the step (3), the compound II is reacted with fuming nitric acid under the condition of acetic acid to synthesize a compound III.
Further preferably, the addition ratio of the compound II, fuming nitric acid and acetic acid is that of the compound II (calculated by mass m (g)) nitric acid (calculated by volume v (ml): acetic acid (calculated as volume v (ml)) =1: 0.5 to 2:1 to 4, preferably 1:1:2.
further, in the step (3), the molar ratio of the compound iii to the chlorinating agent is 1:2 to 5, preferably 1:2.5.
further, in the step (3), the chlorinating agent may be one or more of phosphorus oxychloride, phosgene, sulfonyl chloride, oxalyl chloride and thionyl chloride, and is preferably phosphorus oxychloride.
Further, in the step (3), the compound IV is reduced by adopting a hydrogenation reduction mode of an immobilized metal catalyst to obtain a compound V, wherein the carrier of the catalyst is selected from one of alumina, silicon dioxide or activated carbon, and preferably the activated carbon; the catalyst is selected from one of platinum and nickel palladium.
Further, in the step (3), the mass ratio of the compound IV to the catalyst is 0.01-0.1: 1.
the invention breaks through the thinking formula in the prior art, adopts a synthesis mode of firstly butting halogenated propane and then cyclizing, and surprisingly discovers that the process operation can be simplified, and the product yield can be obviously improved. Meanwhile, the invention adopts the mode of hydrogenation reduction of the nitro by the solid metal catalyst, thereby not only greatly reducing the generation of wastewater, but also remarkably improving the utilization rate of the catalyst and reducing the cost.
Detailed Description
The present invention will be further elucidated with reference to the following embodiments, which should be understood as merely illustrative of the invention and not as limiting the scope of the invention.
Example 1
Synthesis of Compound I
To the reactor were added chloropropane (39.27 g,0.5 mol) and thiourea (45.7 g,0.6 mol), water (400 ml) and heated to reflux for 3 to 4 hours. After the completion of the reaction, the reaction system was evaporated, and ethanol (200 ml) was added with the dry solvent three times.
Ethanol (100 ml) and acetone (300 ml) were then added, and the mixture was stirred for 1 hour. Cooling to crystallize, filtering the crystallized solid, and drying the product under high vacuum overnight to obtain compound i (55.32 g, 0.4638 mol) in 93.6% yield.
Example 2
Synthesis of Compound II
Sodium methoxide (32.4 g;0.6 mol) and dimethyl malonate (79.1 g,0.5 mol) were added to the reactor, methanol (200 ml) was added and dissolved with stirring, and the temperature was raised to 50-55℃to react for 3-4 hours. After the reaction is completed, the system is cooled to 0-5 ℃ and stirred for 30-45min for crystallization.
The precipitated crystals were filtered, washed with pre-chilled methanol (50 ml) and dried under vacuum at 50-55℃for 2-3 hours to give compound II (83.15 g, 0.4476 mol) in 89.3% yield.
Example 3
Synthesis of Compound III
The reactor was cooled to 0deg.C, to which was added Compound II (74.5 g,0.4 mol), fuming nitric acid (75 ml) and acetic acid (150 ml) were added and dissolved with stirring, and the mixture was slowly warmed to room temperature to react for 1.5 hours. Ice water (120 ml) is added into the system after the reaction is finished, the temperature is controlled to be not higher than 30 ℃, and a large amount of crystals are separated out. The mixture was filtered, and the cake was washed twice with water (50 mL) and dried to give compound III (77 g,0.333 mol) in 83.3% yield.
Example 4
Synthesis of Compound IV
To the reactor was added compound III (92.5 g,0.4 mol), phosphorus oxychloride (153.3 g,1 mol) and triethylamine (40.5 g,0.4 mol), and the mixture was refluxed at a temperature of 1.5 hours. After completion of the reaction, ice water (50 mL) was added to the system and stirred for 20 minutes, extraction was performed three times with methylene chloride (100 mL), the organic phases were combined, washed with a saturated sodium hydrogen carbonate solution and a saturated sodium chloride solution (100 mL), dried over anhydrous magnesium sulfate, filtered, and the filtrate was concentrated to give compound iv (92.34 g,0.34 mol) in 86.1% yield.
Example 5
Synthesis of Compound V
To the high pressure reactor was added 5% palladium on carbon (4 g) and compound IV (80.43 g,0.3 mol), methanol (200 ml) was added and mixed with stirring. The nitrogen replaces the air in the kettle for three times, hydrogen is filled until the pressure in the kettle reaches 0.8-1 Mpa, the temperature of the system is raised to 40-45 ℃, and the system is stirred for 4 hours.
After the reaction, slowly cooling to room temperature, discharging hydrogen, filtering the catalyst, flushing the filter cake with methanol, recovering the dry solvent from the filtrate under reduced pressure, and obtaining compound V (63.15 g,0.265 mol) in 88.4% yield and 97.1% purity in liquid phase.
Examples 6 to 9
Other conditions are the same as in example 1, except that the molar ratio of halopropane to thiourea is changed, the kind of halopropane, and the reaction conditions and yields of example 1 and examples 6 to 9 are shown in Table 1.
TABLE 1 different conditions and results for example 1, examples 6-9
Examples | Halopropanes: thiourea | Halogenated propane species | Yield/% |
1 | 1:1.2 | Chloropropane | 93.6 |
6 | 1:1 | Chloropropane | 92.8 |
7 | 1:2 | Chloropropane | 91.1 |
8 | 1:1.2 | Bromopropane | 91.5 |
9 | 1:1.2 | Iodopropane | 89.2 |
Examples 10 to 12
Other conditions were the same as in example 2, except that the molar ratio of compound I, malonate to base was varied, the malonate species; the reaction conditions and yields of example 2 and examples 10-12 are detailed in Table 2.
TABLE 2 different conditions and results for example 2, examples 10-12
Examples | Compound i: malonic ester: alkali | Malonic ester species | Yield/% |
2 | 1:1.2:1:2 | Dimethyl ester | 89.3 |
10 | 1:1:1 | Dimethyl ester | 86.7 |
11 | 1:2:2 | Dimethyl ester | 88.2 |
12 | 1:1.2:1:2 | Diethyl ester | 88.5 |
Examples 13 to 10
Other conditions are the same as in example 3, except that the mass-to-volume ratio of compound II, fuming nitric acid, acetic acid is changed, and the reaction conditions and yields of example 3 and examples 13 to 14 are shown in Table 3.
TABLE 3 different conditions and results for example 3, examples 13-14
Examples 15 to 18
Other conditions are the same as in example 4 except that the molar ratio of compound III to chlorinating agent, the type of chlorinating agent, the reaction conditions and results of example 4 and examples 15-18 are detailed in Table 4.
TABLE 4 different conditions and results for example 4, examples 15-18
Examples 19 to 21
Other conditions are the same as in example 5, except that the mass ratio of the compound IV to the catalyst, the kind of the catalyst, the reaction conditions and the results of example 5 and examples 19 to 21 are shown in Table 5.
TABLE 5 different conditions and results for example 5, examples 19-21
Comparative example
Comparative example 1
Sodium methoxide (32.4 g;0.6 mol) was added to the reactor, thiourea (38.1 g,0.5 mol) and dimethyl malonate (79.3 g,0.6 mol) were added, methanol (200 ml) was added and dissolved with stirring, and the temperature was raised to 50-55℃to react for 3-4 hours. After the reaction is completed, the system is cooled to 0-5 ℃ and stirred for 30-45min for crystallization.
The precipitated crystals were filtered, washed with pre-chilled methanol (50 ml) and dried under vacuum at 50-55deg.C for 2-3 hours to give 6-hydroxy-2-mercaptopyrimidin-4-one (59.89 g, 0.418 mol) in 83.1% yield.
Comparative example 2
To the reactor were added chloropropane (39.27 g,0.5 mol) and 6-hydroxy-2-mercaptopyrimidin-4-one (86.49 g,0.6 mol), water (400 ml) and heated to reflux for 3 to 4 hours. After the completion of the reaction, the reaction system was evaporated, and ethanol (200 ml) was added with the dry solvent three times.
Ethanol (100 ml) and acetone (300 ml) were then added, and the mixture was stirred for 1 hour. Cooling to crystallize, filtering the crystallized solid, and drying the product under high vacuum overnight to obtain compound II (72.34 g, 0.3838 mol) in 77.6% yield.
Comparative examples 3 to 5
Other conditions were the same as in comparative example 1 except that the molar ratio of thiourea, malonate to base, the molar ratio of the malonate species, 6-hydroxy-2-mercaptopyrimidin-4-one to halopropane, the halopropane species, the reaction conditions and yields of comparative example 1 and comparative examples 3-5 were as detailed in Table 6.
TABLE 6 different conditions and results for comparative example 1, comparative examples 3-5
Examples | Thiourea, malonate and base | Malonic ester species | Yield/% |
1 | 1:1.2:1:2 | Dimethyl ester | 83.1 |
3 | 1:1:1 | Dimethyl ester | 79.8 |
4 | 1:2:2 | Dimethyl ester | 82.3 |
5 | 1:1.2:1:2 | Diethyl ester | 81.7 |
Comparative examples 6 to 9
Other conditions are the same as comparative example 2, the molar ratio of halopropane to 6-hydroxy-2-mercaptopyrimidin-4-one, the kind of halopropane, the reaction conditions and yields of comparative example 2 and comparative examples 6-9 are shown in Table 7.
TABLE 7 different conditions and results for comparative example 2, comparative examples 6-9
It should be noted that the foregoing merely illustrates the technical idea of the present invention and is not intended to limit the scope of the present invention, and that a person skilled in the art may make several improvements and modifications without departing from the principles of the present invention, which fall within the scope of the claims of the present invention.
Claims (17)
1. The novel preparation method of the ticagrelor intermediate is characterized in that the synthetic route comprises the following steps:
(1) Thiourea and halogenated propane react and are butted to synthesize the compound I,
x is halogen;
(2) The compound I and malonate synthesize a compound II under the action of alkali,
r1 and R2 are C1-C6 alkyl;
(3) The compound II is nitrified, chloridized and reduced to obtain a compound V,
。
2. the novel process for the preparation of ticagrelor intermediate according to claim 1, wherein in step (1), the molar ratio of halogenated propane to thiourea is 1:1-2.
3. The novel process for the preparation of ticagrelor intermediate according to claim 1, characterized in that in step (1), the molar ratio of halogenated propane to thiourea is 1:1.2.
4. the novel process for the preparation of ticagrelor intermediates according to claim 1, characterized in that in step (2), the molar ratio of compound i, malonate to base is 1: 1-2: 1-2.
5. The novel process for the preparation of ticagrelor intermediates according to claim 1, characterized in that in step (2), the molar ratio of compound i, malonate to base is 1:1.2:1.2.
6. the novel preparation method of ticagrelor intermediate according to claim 1, wherein in step (2), the base is one or more of potassium carbonate, sodium carbonate, potassium hydroxide, sodium hydroxide, potassium tert-butoxide, sodium tert-butoxide and sodium methoxide.
7. The novel process for the preparation of ticagrelor intermediate according to claim 1, wherein in step (2), the base is sodium methoxide.
8. The novel preparation method of ticagrelor intermediate according to claim 1, wherein in step (3), the compound ii is reacted with fuming nitric acid under acetic acid condition to synthesize compound III.
9. The novel preparation method of ticagrelor intermediate according to claim 8, wherein the addition ratio of the compound II, fuming nitric acid and acetic acid is 1g of the compound II, 0.5-2 ml of nitric acid and 1-4 ml of acetic acid.
10. The novel process for preparing ticagrelor intermediate according to claim 8, wherein the addition ratio of the compound II, fuming nitric acid and acetic acid is 1g of compound II, 1ml of nitric acid and 2ml of acetic acid.
11. The novel process for the preparation of ticagrelor intermediates according to claim 1, characterized in that in step (3), the molar ratio of compound iii to chlorinating agent is 1: 2-5.
12. The novel process for the preparation of ticagrelor intermediates according to claim 1, characterized in that in step (3), the molar ratio of compound iii to chlorinating agent is 1:2.5.
13. the novel preparation method of ticagrelor intermediate according to claim 1, wherein in the step (3), the chlorinating agent is one or more of phosphorus oxychloride, phosgene, sulfonyl chloride, oxalyl chloride and thionyl chloride.
14. The novel process for the preparation of ticagrelor intermediates according to claim 1, characterized in that in step (3), the chlorinating agent is phosphorus oxychloride.
15. The novel preparation method of ticagrelor intermediate according to claim 1, wherein in step (3), compound IV is reduced by hydrogenation reduction with an immobilized metal catalyst to obtain compound V, wherein the carrier of the catalyst is selected from one of alumina, silica or activated carbon.
16. The novel preparation method of ticagrelor intermediate according to claim 1, wherein in step (3), compound IV is reduced by hydrogenation reduction with an immobilized metal catalyst to obtain compound V, wherein the carrier of the catalyst is activated carbon.
17. The novel preparation method of ticagrelor intermediate according to claim 1, wherein in the step (3), the compound IV is reduced by hydrogenation reduction with an immobilized metal catalyst, and the catalyst is selected from one of platinum and nickel palladium.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211395626.8A CN115677597B (en) | 2022-11-09 | 2022-11-09 | New preparation method of ticagrelor intermediate |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211395626.8A CN115677597B (en) | 2022-11-09 | 2022-11-09 | New preparation method of ticagrelor intermediate |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115677597A CN115677597A (en) | 2023-02-03 |
CN115677597B true CN115677597B (en) | 2024-03-15 |
Family
ID=85050741
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211395626.8A Active CN115677597B (en) | 2022-11-09 | 2022-11-09 | New preparation method of ticagrelor intermediate |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115677597B (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106008633A (en) * | 2016-05-24 | 2016-10-12 | 北京广博德赛医药技术开发有限责任公司 | Preparation method of Cangrelor intermediate |
CN106496133A (en) * | 2016-10-19 | 2017-03-15 | 青岛云天生物技术有限公司 | The preparation method of ticagrelor midbody |
-
2022
- 2022-11-09 CN CN202211395626.8A patent/CN115677597B/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106008633A (en) * | 2016-05-24 | 2016-10-12 | 北京广博德赛医药技术开发有限责任公司 | Preparation method of Cangrelor intermediate |
CN106496133A (en) * | 2016-10-19 | 2017-03-15 | 青岛云天生物技术有限公司 | The preparation method of ticagrelor midbody |
Also Published As
Publication number | Publication date |
---|---|
CN115677597A (en) | 2023-02-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111233930B (en) | Preparation method of Reidesciclovir | |
CN112047888B (en) | Method for synthesizing enzalutamide | |
KR20110041431A (en) | Solid and crystalline dutasteride and processes for preparation thereof | |
CN115677597B (en) | New preparation method of ticagrelor intermediate | |
CN101376667B (en) | Intermediate for synthesizing azidothimidine, preparation thereof and use in azidothimidine synthesis | |
CN116143706B (en) | Synthesis method of diaminopyrimidine oxide | |
CN108314696B (en) | Utilization method of 2-hydroxy-1, 3, 5-tri-O-benzoyl-alpha-D-ribofuranose crystallization mother liquor | |
JPS5839822B2 (en) | Method for producing PGA type compounds | |
CN112939814B (en) | Preparation method of deuterated dacarbazine intermediate | |
CN111848490B (en) | Preparation method of high-purity ethanesulfonic acid nintedanib | |
CN113004245B (en) | Preparation method of desloratadine | |
CN113845441A (en) | Preparation method of key intermediate of tetrahydrobiopterin | |
JP4437923B2 (en) | Method for producing triterpene derivative | |
CN116283798B (en) | Novel preparation method of urapidil | |
US20090018325A1 (en) | Process for preparing l-nucleic acid derivatives and intermediates thereof | |
CN110746471B (en) | Preparation method of fondaparinux sodium disaccharide intermediate | |
CN117510498A (en) | Preparation method of high-purity linagliptin | |
KR100448642B1 (en) | Method for producing phenyl propionic acid derivatives from 2-phenylpropionic acid by simple processing steps with high yield and purity | |
CN116655652A (en) | New synthesis method of clopidogrel | |
KR19990015053A (en) | Method for preparing 2- (4-halomethylphenyl) propionic acid | |
KR100448640B1 (en) | Method for producing phenyl propionic acid derivatives with high yield and purity | |
JP6780958B2 (en) | 1- (3-carboxypyridyl-2-) -2-phenyl-4-methylpiperazine having a crystal structure and its production method | |
CN118063483A (en) | 4-Trans- (4-alkyl) cyclohexyl benzaldehyde and synthesis method thereof | |
JPS58135843A (en) | Intermediate for 4-phenyl-1,3-benzodiazepine and manufacture | |
CN118005706A (en) | Preparation method of 2',3' -dideoxynucleotide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |